BXP.L - Beximco Pharmaceuticals Limited

LSE - LSE Delayed Price. Currency in GBp
42.50
+0.10 (+0.24%)
At close: 4:22PM BST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close42.40
Open42.75
Bid42.00 x 0
Ask0.00 x 0
Day's Range42.00 - 43.00
52 Week Range30.88 - 50.00
Volume3,846,021
Avg. Volume110,350
Market Cap232.501M
Beta (5Y Monthly)0.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.01 (3.20%)
Ex-Dividend DateNov 21, 2019
1y Target Est84.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Exclusive: Bangladesh's Beximco to begin producing COVID-19 drug remdesivir - COO
      Reuters

      Exclusive: Bangladesh's Beximco to begin producing COVID-19 drug remdesivir - COO

      One of Bangladesh's largest drugmakers, Beximco Pharmaceuticals, will start production this month of the experimental antiviral drug remdesivir, which has shown promise in fighting the new coronavirus, a senior company executive said on Tuesday. Remdesivir, a drug developed by Gilead Sciences, has grabbed attention as one of the most promising treatments for COVID-19, the respiratory disease caused by the novel coronavirus that has killed more than 250,000 people. U.S. drug authorities granted emergency use authorisation last week, paving the way for its broader use in U.S. hospitals, after Gilead provided data showing the drug had helped COVID-19 patients.